1 / 16

“Evidence In The ED” Intravenous Magnesium Sulfate Treatment For Severe Acute Asthma

“Evidence In The ED” Intravenous Magnesium Sulfate Treatment For Severe Acute Asthma. Roger A. Band M.D. Department of Emergency Medicine University of Pennsylvania. Epidemiology of Asthma:.

fostertodd
Download Presentation

“Evidence In The ED” Intravenous Magnesium Sulfate Treatment For Severe Acute Asthma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. “Evidence In The ED”Intravenous Magnesium Sulfate Treatment For Severe Acute Asthma Roger A. Band M.D. Department of Emergency Medicine University of Pennsylvania

  2. Epidemiology of Asthma: • Annually, there are an estimated 1.8 million emergency department visits for acute asthma in the United States, resulting in an estimated 500,000 hospital admissions. • Prevalence has increased in all groups by an estimate 40% during the last decade.

  3. The Study: • IV Magnesium Sulfate in the Treatment of Acute Severe Asthma: A Multicenter Randomized Controlled Trial • Silverman RA, et al. Chest 2002; 122(2):489-497

  4. Study Design • Design: Placebo-controlled, double blind, randomized clinical trial (248 patients enrolled) • Setting: Multicenter cohort-Emergency departments of eight hospitals • Patients: 18-60 years presenting with acute asthma and FEV1<30% predicted on arrival to the ED. • Interventions: All patients received nebulized albuterol at regular intervals and IV methylprednisolone. Two grams of IV magnesium sulfate or placebo were administered 30 min after ED arrival. The primary efficacy end point was FEV1 at 240 min.

  5. Figure 1 Results:

  6. Results:

  7. Results Cont’d:

  8. Study Conclusions: • Overall, patients receiving magnesium had a final FEV1 of 48.2% predicted, compared to 43.5% predicted for patients receiving placebo • Furthermore, patients with an initial FEV1 <25% predicted who received magnesium had a final FEV1 of 45.3% predicted compared to 35.6% for those who received placebo. If the initial FEV1 was >25% predicted, the final FEV1 was 51.1% predicted in the magnesium group and 53.9% predicted in the placebo group.

  9. Confirmatory Studies: • Blochet al. Intravenous Magnesium Sulfate as an adjunct in the Treatment of Acute Asthma. Chest 1995; 107(6):1576-1581 -Conclusion: In patients with severe asthma, there is a significant improvement in FEV1 and hospital admission rate when magnesium is received. • Roweet al. Intravenous Magnesium Sulfate Treatment for Acute Asthma in the Emergency Department: A Systematic Review of the Literature. Annals of Emergency Medicine 2000; 36:181-190 -Conclusion: Current evidence does not clearly support routine use of intravenous magnesium sulfate in all patients with acute asthma presenting to the ED. However, magnesium sulfate appears to be safe and beneficial for patients who present with severe acute asthma.

  10. HUPisms: Judd says magnesium and Rich says plastic!

  11. Take Home Points: • When administered as an adjunct to standard therapy, 2 g of IV magnesium sulfate improves pulmonary function in patients presenting to the ED with severe asthma. • Patients with the most severe airway compromise on ED arrival have the greatest response to magnesium, and patients with an FEV1 closer to 30% of predicted (on ED arrival) have no apparent benefit.

  12. Are you sleeping yet ?

  13. Questions?

More Related